First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes - Executive summary

Xenotransplantation

Volumn 23, Issue 1, 2016, Pages 3-13

  Hering, Bernhard J ^a   Cozzi, Emanuele ^b,c   Spizzo, Thomas ^d   Cowan, Peter J ^e   Rayat, Gina R ^f   Cooper, David K C ^g   Denner, Joachim ^h  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^c CORIT ^*  (Italy)

^d Spring Point Project   (United States)

^e ST VINCENT S HOSPITAL   (Australia)

^f UNIVERSITY OF ALBERTA   (Canada)

^g UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^h ROBERT KOCH INSTITUTE   (Germany)

Author keywords

porcine islets of Langerhans; type 1 diabetes; xenotransplantation

Indexed keywords

CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; CONSENSUS DEVELOPMENT; GOOD MANUFACTURING PRACTICE; GOVERNMENT REGULATION; HUMAN; INFORMED CONSENT; INSULIN DEPENDENT DIABETES MELLITUS; MEDICAL SOCIETY; PANCREAS ISLET TRANSPLANTATION; PATIENT SAFETY; PATIENT SELECTION; PIG; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RISK BENEFIT ANALYSIS; THERAPY EFFECT; TRANSGENIC ANIMAL; TRANSLATIONAL RESEARCH; XENOTRANSPLANTATION; ANIMAL; DIABETES MELLITUS, TYPE 1; LEGISLATION AND JURISPRUDENCE; PUBLICATION; XENOGRAFT;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; HUMANS; INFORMED CONSENT; ISLETS OF LANGERHANS TRANSPLANTATION; PATIENT SELECTION; PERIODICALS AS TOPIC; SWINE; TRANSPLANTATION, HETEROLOGOUS;

EID: 84960803488     PISSN: 0908665X     EISSN: 13993089     Source Type: Journal    
DOI: 10.1111/xen.12231     Document Type: Conference Paper

References (49)

1. Hering BJ, Cooper DK, Cozzi E, et al., The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes- executive summary. Xenotransplantation 2009; 16: 196-202.
2. Cozzi E, Tallacchini M, Flanagan EB, et al., The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-chapter 1: Key ethical requirements and progress toward the definition of an international regulatory framework. Xenotransplantation 2009; 16: 203-214.
3. Schuurman HJ,. The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-chapter 2: Source pigs. Xenotransplantation 2009; 16: 215-222.
4. Korbutt GS,. The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-chapter 3: Pig islet product manufacturing and release testing. Xenotransplantation 2009; 16: 223-228.
5. Cooper DK, Casu A,. The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-chapter 4: Pre-clinical efficacy and complication data required to justify a clinical trial. Xenotransplantation 2009; 16: 229-238.
6. Denner J, Schuurman HJ, Patience C,. The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-chapter 5: Strategies to prevent transmission of porcine endogenous retroviruses. Xenotransplantation 2009; 16: 239-248.
7. O'Connell PJ,. The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-chapter 6: Patient selection for pilot clinical trials of islet xenotransplantation. Xenotransplantation 2009; 16: 249-254.
8. Vanderpool HY,. The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-chapter 7: Informed consent and xenotransplantation clinical trials. Xenotransplantation 2009; 16: 255-262.
9. Arcidiacono JA, Evdokimov E, Lee MH, et al., Regulation of xenogeneic porcine pancreatic islets. Xenotransplantation 2010; 17: 329-337.
10. van der Windt DJ, Bottino R, Kumar G, et al., Clinical islet xenotransplantation: How close are we? Diabetes 2012; 61: 3046-3055.
11. Samy KP, Martin BM, Turgeon NA, et al., Islet cell xenotransplantation: A serious look toward the clinic. Xenotransplantation 2014; 21: 221-229.
12. Wijkstrom M, Bottino R, Cooper DK,. Limitations of the pig-to-non-human primate islet transplantation model. Xenotransplantation 2013; 20: 2-4.
13. Cooper DK, Bottino R, Satyananda V, et al., Toward clinical islet xenotransplantation-are revisions to the IXA guidelines warranted? Xenotransplantation 2013; 20: 68-74.
14. Cozzi E, Toenjes RR, Gianello P, et al., First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-Chapter 1: Update on national regulatory frameworks pertinent to clinical islet xenotransplantation. Xenotransplantation 2016; 23: 14-24.
15. Spizzo T, Denner J, Gazda LS, et al., First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-Chapter 2a: Source pigs-preventing xenozoonoses. Xenotransplantation 2016; 23: 25-31.
16. Cowan PJ, Ayares D, Wolf E, et al., First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-Chapter 2b: Genetically modified source pigs. Xenotransplantation 2016; 23: 32-37.
17. Rayat GR, Gazda LS, Hawthorne WJ, et al., First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-Chapter 3: Porcine islet product manufacturing and release testing criteria. Xenotransplantation 2016; 23: 38-45.
18. Cooper DKC, Bottino R, Gianello P, et al., First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-Chapter 4: Pre-clinical efficacy and complication data required to justify a clinical trial. Xenotransplantation 2016; 23: 46-52.
19. Denner J, Toenjes RR, Takeuchi Y, et al., First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-Chapter 5: Recipient monitoring and response plan for preventing disease transmission. Xenotransplantation 2016; 23: 53-59.
20. Hering BJ, O'Connell P,. First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-Chapter 6: Patient selection for pilot clinical trials of islet xenotransplantation. Xenotransplantation 2016; 23: 60-76.
21. WORLD HEALTH ORGANIZATION. Fifty-Seventh World Health Assembly Resolution WHA57.18. http://www who int/transplantation/en/A57-R18-en pdf?ua=1 2004 [accessed on 02 February 2016].
22. First WHO global consultation on regulatory requirements for xenotransplantation clinical trials: Changsha, China, 19-21 November 2008. The Changsha Communique. Xenotransplantation 2009; 16: 61-63.
23. WORLD HEALTH ORGANIZATION. Second WHO Global Consultation on Regulatory Requirements for Xenotransplantation Clinical Trials. http://www who int/transplantation/xeno/report2nd-global-consultation-xtx pdf 2011 [accessed on 02 February 2016].
24. Van Der Windt DJ, Bottino R, Casu A, et al., Long-term controlled normoglycemia in diabetic non-human primates after transplantation with hCD46 transgenic porcine islets. Am J Transplant 2009; 9: 2716-2726.
25. Thompson P, Badell IR, Lowe M, et al., Islet xenotransplantation using gal-deficient neonatal donors improves engraftment and function. Am J Transplant 2011; 11: 2593-2602.
26. Hawthorne WJ, Salvaris EJ, Phillips P, et al., Control of IBMIR in neonatal porcine islet xenotransplantation in baboons. Am J Transplant 2014; 14: 1300-1309.
27. Bottino R, Wijkstrom M, van der Windt DJ, et al., Pig-to-monkey islet xenotransplantation using multi-transgenic pigs. Am J Transplant 2014; 14: 2275-2287.
28. Cong L, Ran FA, Cox D, et al., Multiplex genome engineering using CRISPR/Cas systems. Science 2013; 339: 819-823.
29. Hai T, Teng F, Guo R, et al., One-step generation of knockout pigs by zygote injection of CRISPR/Cas system. Cell Res 2014; 24: 372-375.
30. Li P, Estrada JL, Burlak C, et al., Efficient generation of genetically distinct pigs in a single pregnancy using multiplexed single-guide RNA and carbohydrate selection. Xenotransplantation 2015; 22: 20-31.
31. Wijkstrom M, Bottino R, Iwase H, et al., Glucose metabolism in pigs expressing human genes under an insulin promoter. Xenotransplantation 2015; 22: 70-79.
32. FDA. Application of Current Statutory Authorities to Human Somatic Cell Therapy Products and Gene Therapy Products: Notice 1993 58 FR 53248. 10-14-0993. http://www.fda.gov/downloads/BiologicsBloodVaccines/SafetyAvailability/UCM148113.pdf. [accessed on 02 February 2016].
33. Kessler DA, Siegel JP, Noguchi PD, et al., Regulation of somatic-cell therapy and gene therapy by the food and drug administration. N Engl J Med 1993; 329: 1169-1173.
34. Federal Food, Drug and Cosmetic Act, Title 21, U.S.C. 321. 7-13-2009. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/FDCActChaptersIandIIShortTitleandDefinitions/ucm086297.htm. [accessed on 02 February 2016].
35. Weber DJ, McFarland RD, Irony I,. Selected Food and Drug Administration review issues for regulation of allogeneic islets of langerhans as somatic cell therapy. Transplantation 2002; 74: 1816-1820.
36. FDA. Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy. 1998. http://www.fda.gov/biologicsbloodvaccines/guidancecompliance-regulatoryinformation/guidances/cellularandgenetherapy/ucm072987.htm. [accessed on 02 February 2016].
37. FDA. Guidance for Industry: Considerations for Allogeneic Pancreatic Islet Cell Products. 2008. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/UCM166165.pdf. [accessed on 02 February 2016].
38. ASTM INTERNATIONAL. ASTM F2064-00: Standard Guide for Characterization and Testing of Alginates as Starting Materials Intended for Use in Biomedical and Tissue-Engineered Medical Products Applications. http://www astm org/search/fullsite-search html?query=ASTM%20standard%20F2064&resStart=0&resLength=10&2006 [accessed on 02 February 2016].
39. ASTM INTERNATIONAL. ASTM F2315-03: Standard Guide for Immobilization or Encapsulation of Living Cells or Tissue in Alginate Gels. http://www astm org/search/fullsite-search html?query=ASTM%20standard%20F2315-03,%202003& 2003 [accessed on 02 February 2016].
40. U.S.DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION CENTER FOR BIOLOGICS EVALUATION AND RESEA-RCH (CBER). Guidance for Industry: Source Animal, Product, Preclinical, and Clinical Issues Concerning the Use of Xenotransplantation Products in Humans. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Xenotransplantation/ucm0-74354.htm. [accessed on 02 February 2016].
41. EUROPEAN MEDICINES AGENCY (EMEA) COMMITTEE FOR MEDICINAL PRODUCTS FOR HUM-AN USE (CHMP). Guideline on Xenogeneic Cell-Based Medicinal Products. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/12/WC-500016936.pdf [accessed on 02 February 2016].
42. Health Research Council of New Zealand Gene Technology Advisory Committee. Guidelines for Preparation of Applications Involving Clinical Trials of Xenotransplantation in New Zealand. http://www.hrc.govt.nz/sites/default/files/GTAC%20Guidelines%20for%20Preparation%20of%20Applications%20Involving%20Clinical%20Trials%20of%20Xenotransplantation%20in%20NZ.pdf [accessed on 02 February 2016].
43. U.S.Department of Health And Human Services Food And Drug Administration Center For Biologics Evaluation And Research. Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products: Guidance for Industry. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceCompliance-RegulatoryInformation/Guidances/CellularandGeneTherapy-/UCM359073.pdf [accessed on 02 February 2016].
44. Matsumoto S, Tan P, Baker J, et al., Clinical porcine islet xenotransplantation under comprehensive regulation. Transplant Proc 2014; 46: 1992-1995.
45. Bartlett ST, Markmann JF, Johnson P, et al., Report from IPITA-TTS opinion leaders meeting on the future of beta-cell replacement. Transplantation 2016; 100 (Suppl. 2): S1-S44.
46. Beck RW, Raghinaru D, Wadwa RP, et al., Frequency of morning ketosis after overnight insulin suspension using an automated nocturnal predictive low glucose suspend system. Diabetes Care 2014; 37: 1224-1229.
47. Haidar A, Legault L, Messier V, et al., Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: An open-label randomised controlled crossover trial. Lancet Diabetes Endocrinol 2015; 3: 17-26.
48. Rezania A, Bruin JE, Arora P, et al., Reversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells. Nat Biotechnol 2014; 32: 1121-1133.
49. Pagliuca FW, Millman JR, Gurtler M, et al., Generation of functional human pancreatic beta cells in vitro. Cell 2014; 159: 428-439.